8-K - Harvard Bioscience, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Harvard Bioscience, Inc. furnished its corporate investor presentation dated March 2026 under Item 7.01 Regulation FD Disclosure, highlighting FY25 financial results including $87 million revenue, 58% adjusted gross margin, and $8 million adjusted EBITDA, recent leadership changes, debt refinancing, manufacturing consolidation, and FY26 growth guidance. This provides investors with strategic updates and financial outlook focused on translational science tools.

Key Takeaways

1FY25 revenue of $87 million

2FY25 adjusted gross margin of 58%

3FY25 adjusted EBITDA of $8 million

4FY26 revenue growth guidance of 2-4%

5Debt maturity extended to 2029 generating $3 million annual cash savings; BroadOak invested $7.5 million in convertible notes

6John Duke appointed CEO effective July 2025; Mark Frost permanent CFO in March 2026

7Phased closure of Holliston, MA plant expected to deliver $3 million adjusted EBITDA improvement in 2027

Current Report Details

Event Type

Regulation Fd

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

7.01

of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Ac

Regulation Fd

9.01

Financial Statements and Exhibits. (d) Exhibits. EXHIBIT NUMBER EXHIBIT DESCRIPTION 99.1 Corporate slide presentation of Harvard Bioscience, Inc., dated March 2

Exhibits Only

Source Document

Exhibits (2)

8-K

FORM 8-K

99.1

EXHIBIT 99.1